FindTrial
Sign In

A study comparing pain relief from intravenous vs nerve block dexmedetomidine with bupivacaine in ultrasound guided adductor canal block for knee replacement surgery

A randomized comparative study to evaluate the analgesic effect of intravenous versus perineural dexmedetomidine as an adjuvant to bupivacaine in ultrasound-guided adductor canal block in patients undergoing total knee arthroplasty. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/093839
Enrollment
70
Registered
2025-08-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M171- Unilateral primary osteoarthritisof knee

Interventions

Intervention1: Effect of intravenous DEXMEDETOMIDINE for duration of one year: A randomized comparative study to evaluate the analgesic effect of intravenous dexmedetomidine as an adjuvant to bupivac

Sponsors

Sawai Maan Singh medical college
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Undergoing total knee replacement Informed written conscent American society of anesthesiologists grade 1,2 and 3

Exclusion criteria

Exclusion criteria: Psychiatric illness Peripheral sensorineural deficit Allergic to study drugs Infection at site of block Compartment syndrome

Design outcomes

Primary

MeasureTime frame
no significant difference in onset of sensory block between IV and perineural administration of dexmedetomidine as an adjuvant to bupivacaine in USG guided adductor canal block in patients undergoing total knee arthroplasty.Timepoint: 5min ,10mins,15 mins,20 mins postoperative—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactDr Mamta Khandelwal

SMS Medical College Jaipur

drmamtakhandelwal@gmail.com9929338174

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026